Avalyn completes enrollment in Phase 2b trial of inhaled pirfenidone

June 17, 2026 8:00 AM

Avalyn Pharma Inc. (Nasdaq: AVLN) announced it has completed target enrollment of 375 patients in its Phase 2b MIST clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found